Composition of Certain Financial Statement Captions (Tables)

9 Months Ended

Sep. 30, 2014



(In thousands)	September 30, 2014			December 31, 2013
Accounts receivable, net
Accounts receivable	$	22,642		$	21,652
Less: allowance for doubtful accounts	(1,432		)	(1,885		)
	$	21,210		$	19,767
Inventories, net
Finished products	$	11,355		$	13,374
Work in-process	1,040			1,350
Raw materials	4,859			4,132
Less: inventory reserve	(592		)	(777		)
	$	16,662		$	18,079
Prepaid expenses and other current assets
Prepaid supplies	$	1,626		$	945
Prepaid insurance	944			892
Pharmsynthez notes receivable	—			6,151
Other receivables	565			1,985
Taxes recoverable	1,292			3,458
Other	2,591			5,653
	$	7,018		$	19,084
Intangible assets, net:
Technologies	$	52,694		$	51,660
Customer relationships	22,153			22,725
Product registrations	8,941			9,692
Trade names	3,509			3,669
Covenants not to compete	8,652			8,671
Other	1,131			2,519
Less: accumulated amortization	(31,527		)	(24,403		)
	$	65,553		$	74,533
Accrued expenses:
Taxes payable	$	325		$	702
Deferred revenue	5,147			7,639
Clinical trials	5,524			3,342
Professional fees	766			402
Employee benefits	5,614			4,399
Deferred acquisition payments, net of discount	—			5,465
Contingent consideration	25,857			28,047
Other	12,321			15,878
	$	55,554		$	65,874



(In thousands)	September 30, 2014		December 31, 2013
Other long-term liabilities:
Contingent consideration – OPKO Renal	$	35,425	$	34,401
Contingent consideration – OPKO Health Europe	292		504
Contingent consideration – OPKO Diagnostics	9,237		8,340
Contingent consideration – CURNA	423		316
Mortgages and other debts payable	2,627		3,270
Deferred tax liabilities	164,512		166,435
Other, including deferred revenue	3,658		1,509
	$	216,174	$	214,775

The following table summarizes the changes in Goodwill during the nine months ended September 30, 2014.